Bristol-Myers' stock rises on promising lung cancer drug data
This article was originally published in Scrip
Executive Summary
Shares of Bristol-Myers Squibb rose almost 7% after the company reported that its experimental drug nivolumab showed a long-term survival benefit in lung cancer patients treated in an early stage study.